Core Insights - Tempus AI (TEM) is positioned at the intersection of diagnostics, data, and artificial intelligence, focusing on a precision medicine platform to aid informed decision-making for healthcare professionals and researchers [1] Revenue Performance - In 2025, Tempus generated $1.27 billion in total revenues, with significant growth in both Diagnostics and Data and Applications segments [2] - Diagnostics accounted for $955.4 million, approximately 75% of total revenue, while Data and Applications contributed $316.4 million, or about 25% of total revenues [5][7] - Diagnostics revenues increased by 111.5% year-over-year, with a notable 121.6% growth in Q4 2025, driven by 29% growth in Oncology volume and 23% growth in Hereditary volume [6] Business Model and Offerings - Tempus aggregates multimodal data from clinical care and laboratory testing, utilizing AI to provide actionable insights for various stakeholders [3] - The company’s revenue model includes two main segments: Genomics, which focuses on oncology and hereditary testing, and Data and Services, which commercializes de-identified datasets and clinical trial services [4] Growth Drivers - The acquisition of Ambry Genetics in February 2025 enhanced Tempus's capabilities in inherited cancer risk testing and rare disease panels, contributing to revenue growth [6] - Data and Applications segment saw a 25.1% year-over-year revenue increase in Q4 2025, with Insights revenues growing by 69.5% [8] AI Applications and Regulatory Milestones - Tempus is developing AI applications beyond core testing, including tools for care gap identification and imaging platforms that integrate AI into diagnostic workflows [9][10] - The company has received regulatory clearances that support broader use cases, enhancing its positioning with life sciences partners [10] Investor Considerations - Key factors for investors include pricing and reimbursement progress, the conversion of contracted data value into recognized revenues, and the potential for operating leverage as adjusted EBITDA improves [12][13] - The company’s current Zacks Rank is 4 (Sell), indicating near-term earnings estimate trends, with growth durability and pricing gains being critical for future sentiment [14]

Core Insights - Tempus AI, Inc. (TEM) has announced a collaboration with Median Technologies to integrate Median's eyonis LCS solution into the Tempus Pixel platform, enhancing AI capabilities in lung cancer screening and clinical decision-making [1][3][9] Company Developments - The eyonis LCS is an AI-enabled software-as-a-medical-device (SaMD) for lung cancer screening that has received FDA 510(k) clearance, facilitating its commercialization and clinical adoption [2] - The integration aims to support earlier and more accurate disease detection, assist radiologists with complex caseloads, and ultimately reduce preventable lung cancer deaths through improved access to advanced screening tools [3][5] - The collaboration is expected to strengthen Tempus AI's imaging-AI portfolio and expand the adoption of its Pixel platform, enhancing end-to-end lung cancer screening and workflow efficiency [5][9] - Tempus AI's current market capitalization stands at $9.24 billion [7] Market Context - The artificial intelligence in precision medicine market is projected to reach $4.28 billion by 2026, with a compound annual growth rate (CAGR) of 34.3% through 2035, driven by the increasing prevalence of cancer and demand for AI-powered diagnostic tools [12] - Research indicates that only 20% of eligible individuals in the U.S. underwent lung cancer screening in 2024, suggesting a significant adoption gap that the eyonis LCS aims to address [10]

Core Insights - Tempus AI (TEM) stock has achieved a 105% gain over the past year, driven by strong performance in its Genomics and Data segments, exceeding initial expectations for 2025 [1] - The adoption of artificial intelligence (AI) has been a significant catalyst for the company's product portfolio, enhancing the value proposition of its offerings [1] Upsides for TEM Stock - Tempus has received multiple 510(k) clearances from the FDA for its diagnostic and imaging solutions, including the RNA-based Tempus xR IVD device and the updated Tempus Pixel AI-powered cardiac imaging platform [2][3] - The company also secured FDA clearance for its Tempus ECG-Low EF software, which utilizes AI to identify patients with low left ventricular ejection fraction [3] Stable Solvency - Tempus has a well-capitalized balance sheet, ending the last reported quarter with cash and cash equivalents of $760 million and no current debt, providing flexibility amid macroeconomic uncertainty [4] - Long-term debt stood at $1.25 billion, with manageable leverage levels, reflecting a conservative capital structure approach [5] Approach Toward Profitability - The company has shown early signs of profitability, achieving positive adjusted EBITDA of $1.5 million, marking a significant milestone in its financial trajectory [6] - Gross profit nearly doubled year over year in the third quarter, indicating strengthening underlying business economics [7] Price Comparison - Over the past year, TEM stock has outperformed the industry and the S&P 500, as well as competitors like Exact Sciences and GE HealthCare Technologies [9] Average Target Price - Tempus is currently trading 28.6% below its average Zacks price target, indicating strong near-term upside potential [10] Key Challenge for TEM - Despite positive adjusted EBITDA, GAAP losses persist due to stock-based compensation and amortization of acquired intangibles, raising concerns about the quality of profitability [12] - The lack of GAAP net loss guidance limits visibility into the timeline for achieving sustainable GAAP profitability [13] Estimate Revision Trend - Estimates for TEM have narrowed from a loss of 68 cents per share to a loss of 64 cents for 2025 over the past 90 days [15] Strategic Positioning - Tempus' growing portfolio of FDA-cleared diagnostic and AI-driven imaging solutions reinforces its technological leadership and credibility in clinical and life sciences markets [16] - The company is well-positioned to continue investing in AI innovation and data infrastructure, although GAAP losses and limited visibility into sustainable profitability remain key considerations [16]

Core Insights - Tempus AI (TEM) is advancing its suite of algorithms and diagnostic software across multiple medical fields, including oncology, digital pathology, radiology, cardiology, and neuropsychology [1][9] Company Developments - Tempus has partnered with Northwestern University's Abrams Center to utilize AI for rapid advancements in Alzheimer's disease research, employing its AI-powered data analytics platform, Lens, to analyze genomic data [2] - The company has received two new FDA 510(k) clearances for its updated Tempus Pixel cardiac imaging platform and ECG–Low EF software, enhancing capabilities in cardiac MR image analysis and identifying patients with reduced left ventricular ejection fraction [3][9] - Strategic acquisitions have bolstered Tempus' position in the market, including the acquisition of Arterys in 2022 for AI tools in imaging data analysis and Paige, which brought a dataset of nearly 7 million clinically annotated pathology slides [4][9] Industry Context - GE HealthCare has launched the Voluson Performance series for women's health ultrasound and is acquiring icometrix for AI-powered brain imaging analysis [5] - NANO-X IMAGING LTD received CE mark certification for its Nanox.ARC system, which generates tomographic images from a single sweep [6] Stock Performance - Tempus' stock has increased by 74% over the past year, significantly outperforming the industry, which saw a decline of 1.5%, while the S&P 500 composite rose by 14.5% [7] Valuation Metrics - Tempus currently has a forward 12-month Price-to-Sales (P/S) ratio of 8.76X, compared to the industry average of 5.77X, indicating a higher valuation [10] Earnings Estimates - The loss per share estimate for Tempus AI for 2025 has remained unchanged over the past 30 days, with estimates at -0.05 for the current quarter, -0.13 for the next quarter, and -0.65 for the current year [11][12]

Summary of Tempus AI Conference Call Company Overview - **Company**: Tempus AI - **Industry**: Life Science Tools and Diagnostics Key Points Financial Performance - Achieved first positive Adjusted EBITDA in Q3, a long-term goal set for the company [2][3] - Projected top-line growth of approximately 25% annually over the next three years, with plans to reinvest two-thirds of incremental growth profit back into the business [2][3] Data and Product Differentiation - Connected to over 5,000 institutions with access to over 45 million patient records, providing a large database for biopharma collaborations [5][6] - Data business operates on multi-year subscriptions, licensing cohorts of data to improve clinical trial design and drug development [8][9] - Acquisition of Ambry allows for earlier patient interaction and expansion into hereditary screening and rare diseases [10][11][12] Strategic Partnerships - Multi-year deal with AstraZeneca valued at $320 million and a $200 million deal with Pathos AI, focusing on leveraging extensive data for drug discovery [13][14] - Collaboration with Personalis to offer both tumor-informed and tumor-naive assays, aiming to be a one-stop shop for physicians [31][33] Product Development and Market Strategy - Launch of xT CDx solid tumor DNA test with a $4,500 reimbursement rate, aiming for significant market uptake by 2026 [17][18] - Plans to expand into other disease areas, including cardiology and rare diseases, while maintaining a focus on profitability [21][22] Revenue and Margin Outlook - Average reimbursement for tests is approximately $1,600, with expectations for long-term positive reimbursement trends [20] - Data margins are stable, with potential for high margins in AI applications as the business grows [24] Research and Development Focus - Investments primarily in traditional R&D and technology development, with a cautious approach to expanding the sales force [28][29] - Continuous evaluation of new diagnostic tests based on physician needs while maintaining a streamlined customer experience [34] Capital Deployment Strategy - Active in M&A, with a focus on acquiring companies that enhance data and AI capabilities, while balancing build versus buy strategies [39][40] Future Outlook - Long-term vision includes the potential for AI applications to become the largest segment of the business, with ongoing efforts to ensure reimbursement for new technologies [30][38] Additional Insights - The company emphasizes the importance of providing insights to physicians to improve patient care and outcomes, particularly in oncology [19][18] - The integration of Ambry's data is seen as a multi-year effort, with excitement about the potential insights that can be derived [11][12]

Core Insights - Tempus AI, Inc. reported a narrower adjusted loss of 11 cents per share for Q3 2025, outperforming the Zacks Consensus Estimate by 31.3% [1] - The company experienced a significant revenue increase of 84.7% year-over-year, totaling $334.2 million, which also exceeded the Zacks Consensus Estimate by 2.4% [2] Revenue Breakdown - Genomics revenues reached $252.9 million, marking a 117.2% increase year-over-year, with oncology testing contributing $139.5 million (up 31.7%) and hereditary testing contributing $102.6 million (up 32.8%) [3] - The Data and Services product line generated $81.3 million in sales, reflecting a 26.1% year-over-year growth, driven by a 37.6% increase in data licensing [4] Margin Performance - Gross profit for Q3 was $209.9 million, up 98.4% from the previous year, with an adjusted gross margin of 62.8%, an increase of 432 basis points [5] - Total adjusted operating expenses rose to $232.8 million, an 80.8% increase year-over-year, resulting in an operating loss of $22.9 million, unchanged from the previous year [5] Liquidity Position - As of the end of Q3 2025, the company had cash and cash equivalents of $655.9 million, a significant increase from $186.3 million at the end of Q2 [6] - Cumulative net cash used in investing activities was $387.6 million, compared to $122.4 million a year ago [6] Full-Year Outlook - Tempus raised its 2025 revenue guidance to approximately $1.265 billion, indicating nearly 80% annual growth, slightly below the Zacks Consensus Estimate of $1.26 billion [7] - Adjusted EBITDA for the year is now expected to be $20 million, up from the previous estimate of $5 million [9] Strategic Developments - The company achieved several milestones in Q3, including the acquisition of Paige, an AI company in digital pathology, and obtaining FDA clearance for multiple diagnostic devices [10] - Despite the operating loss, the raised revenue guidance is seen as a positive indicator for the stock [10]

Core Insights - Tempus AI Inc. has achieved significant regulatory milestones in AI-driven diagnostics, including FDA 510(k) clearances for multiple devices in 2025 [1][8] Regulatory Approvals - In September 2025, Tempus received FDA 510(k) clearance for its RNA-based Tempus xR IVD device, which aids drug development through advanced RNA sequencing [1][8] - The Tempus xR IVD assay utilizes next-generation sequencing technology to detect gene rearrangements in RNA from tumor tissue specimens [2] - The updated Tempus Pixel, an AI-powered cardiac imaging platform, also received FDA clearance in September, enhancing its capabilities for cardiac MR image analysis with new T1 and T2 inline maps [3][8] - In July 2025, Tempus obtained FDA 510(k) approval for Tempus ECG-Low EF, an AI software that identifies patients with low left ventricular ejection fraction (LVEF ≤ 40%) [4][8] Competitive Landscape - GE HealthCare received FDA 510(k) clearance for its Revolution Vibe CT system, which improves cardiac diagnoses and reduces exam time [5] - Guardant Health gained FDA approval for its Guardant360 CDx as a companion diagnostic for advanced breast cancer patients [6] Stock Performance - Tempus AI shares have increased by 105.8% over the past year, outperforming the industry growth of 28.4% and the S&P 500's 18.8% [6][8] Valuation Metrics - Tempus AI currently trades at a forward Price-to-Sales (P/S) ratio of 10.26X, significantly higher than the industry average of 5.87X [9] Earnings Estimates - The loss per share estimate for Tempus AI for 2025 has remained unchanged over the past 30 days [10]

Core Insights - Tempus AI, Inc. (TEM) is set to report its third-quarter 2025 results on November 3, with an adjusted loss of 22 cents in the last quarter, which was better than the Zacks Consensus Estimate of a loss of 23 cents per share [1] - The company has exceeded earnings estimates in three of the last four quarters, with an average negative earnings surprise of 0.72% [1] Revenue and Earnings Estimates - The Zacks Consensus Estimate for third-quarter revenues is $326.9 million, reflecting an 80.7% increase compared to the same period last year [2] - The loss per share estimate for the third quarter has remained steady at 16 cents over the past 30 days [2] Stock Performance - Tempus AI's stock experienced a 48% gain during the third quarter of 2025, outperforming the broader industry gain of 6% and the S&P 500's 9.8% increase [3][4] - The company outperformed competitors in the health infotech sector, such as 10x Genomics (2.8% gain) and SOPHiA GENETICS (35.3% gain) [4] Strategic Developments - The acquisition of Paige, valued at $81.25 million, is expected to enhance Tempus' digital pathology dataset and AI capabilities, adding nearly 7 million digitized pathology slide images [8] - The company achieved several regulatory milestones, including multiple FDA clearances for its diagnostics and imaging products, which strengthen its market position [10] Business Segments and Demand - The Genomics segment is anticipated to show improvement due to increased volume in oncology testing and strong demand for proprietary data licensing and AI solutions [9] - The recent collaboration with AstraZeneca highlights growing pharmaceutical interest in Tempus' extensive molecular and clinical datasets [9] Financial Outlook - Tempus AI's second-quarter gross profit more than doubled, and adjusted EBITDA losses narrowed, indicating progress towards profitability [11] - The company expects an adjusted EBITDA of $5 million for the full year 2025, with meaningful progress anticipated in the upcoming quarter [11] Valuation Concerns - TEM's stock is currently considered overvalued, trading at a forward price-to-sales ratio of 10.26, significantly higher than the industry average of 5.83 [13] - The stock's premium valuation and lack of near-term profitability may limit short-term gains [16] Market Positioning - The AI market is projected to grow rapidly, positioning Tempus AI to capitalize on emerging opportunities in healthcare [14] - The company is focused on advancing healthcare outcomes, presenting an attractive investment prospect in the AI and healthcare sectors [14]

Core Insights - Tempus AI has seen a significant increase in its stock price, rising 155% since its IPO price of $37, with shares reaching a high of $104 on October 9 before closing near $94 on October 13 [1][2] Recent Developments - The company received 510(k) clearance from the FDA for its AI-powered cardiac imaging platform, Tempus Pixel, which provides numerical data about heart tissue health and automates image reporting, leading to a nearly 14% increase in shares [2] - Tempus also gained 510(k) clearance for its Tempus xR IVD device, which analyzes cancerous cells through RNA sequencing, aimed at assisting drug companies in designing better clinical trials [3] - An executive order signed by President Trump on September 30, promoting AI in pediatric cancer research, contributed to a 9% rise in Tempus shares, aligning with the company's mission [4] Market Analysis - The consensus price target for Tempus is just under $72, indicating a potential downside of 24%, although recent targets from analysts like HC Wainwright and Guggenheim suggest modest upside potential of 0% to 4% [5][6] - Tempus trades at a forward enterprise value to sales (EV/S) ratio of around 12x, significantly higher than the average of 6x for U.S. large-cap life sciences tools and services stocks, suggesting the stock may be overvalued [7] - Despite the positive developments, there is uncertainty regarding the market adoption of the newly cleared devices, and the company needs to demonstrate that these products can generate meaningful financial results [8] Analyst Sentiment - Tempus AI currently holds a Hold rating among analysts, with some suggesting that there are better investment opportunities available [10]

Core Insights - Tempus AI's stock surged to a record high following FDA clearance of its new RNA analysis device, which aids drugmakers in understanding disease mechanisms and targeting specific conditions [1][2] - The FDA clearance is seen as a significant step in unlocking the full potential of RNA sequencing for therapeutic development, according to Tempus AI's Chief Scientific Officer [2] - Following the FDA announcement, Tempus AI's stock increased over 5% to $92.92, surpassing a profit-taking zone after breaking out of a cup base pattern [2] Company Performance - Tempus AI stock ranks No. 33 on the IBD 50 list of elite growth stocks, indicating strong market performance [3] - The stock has shown a rising relative strength rating, achieving an upgrade to 88, reflecting its increasing market leadership [5][7] Market Context - The weight-loss industry, valued at $186 billion, is experiencing a surge, which may contribute to the overall market dynamics affecting companies like Tempus AI [1] - Other companies in the biopharma space, such as Merck and Pfizer, are also making significant moves, indicating a competitive landscape in therapeutic development [4]